Patents Represented by Attorney Julian S. Levitt
  • Patent number: 5068185
    Abstract: The GAL4 protein is rate-limiting in quantity as a positive regulator for galactose-inducible promoters in strains of yeast. Novel strains are described in which the GAL4 protein can be overproduced in a regulatable fashion. These strains are useful for the regulatable expression in yeast of heterologous genes whose expression is driven by a galactose-inducible promoter.
    Type: Grant
    Filed: July 10, 1986
    Date of Patent: November 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: James E. Hopper, Loren D. Schultz, Kathryn J. Hofmann, Ronald W. Ellis
  • Patent number: 4816564
    Abstract: The entire hepatitis B Virus pre-S antigen gene linked in one contiguous reading frame to the hepatitis B virus surface antigen gene has been expressed in Saccharomyces cerevisiae. The expressed protein aggregates into a particulate form which displays the major antigenic sites encoded by both domains, thereby highlighting the utility of yeast as a host for the expression of pre-S domains. This protein is useful in in vitro diagnostic systems and as a vaccine for the treatment and prevention of hepatitis B virus-induced diseases and/or infections.
    Type: Grant
    Filed: January 31, 1986
    Date of Patent: March 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Arpi Hagopian, Peter J. Kniskern
  • Patent number: 4816443
    Abstract: Novel peptides having potent natriuretic activity are disclosed with the following amino acid sequence: ##STR1## wherein Z is H, acetyl, Boc or Ser-Leu, E is Phe, NMP, OMT, ChA, F is Gly or DAl, G is Ala or Gly, H is Arg or DAr, Pro, Lys or Dly, I is Ile, Met, MeO, MO.sub.2, Leu, Nle, or Val, J is Aib, .alpha.MG or .alpha.MA, K is Arg or Lys, L is Ile or Val, M is Aib, Gly, Ala or DAl, N is Ala, NMA, Pro, Phe or NMP, O is Gln, DGl, Ala or DAl, P is Ser, His, Arg or Lys, Q is Gly, Pro, Ala or Dal, R is Leu, Phe or ChA, S is Gly, Ala or Dal, Arg or DAr, T is Asn DAs, Ala or Dal, U is Ser, DSe, Ala or DAl, V is Phe, DPh, Ala or DAl, Y is -OH or -NH.sub.2 and n is 0 or 1. Also included are the lower alkyl esters and the physiologically acceptable metal salts and acid addition salts of the foregoing peptides. Unless indicated otherwise all optically active amino acids have the L-configuration.
    Type: Grant
    Filed: May 19, 1987
    Date of Patent: March 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Stephen F. Brady, Ruth F. Nutt
  • Patent number: 4812559
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human convalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.
    Type: Grant
    Filed: March 23, 1987
    Date of Patent: March 14, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Paul M. Keller, Robert S. Lowe, Andrew J. Davison
  • Patent number: 4812590
    Abstract: Derivatives of 4-hydroxyanisole carbamate are suitable as prodrugs for the delivery and concentration of 4-hydroxyanisole in melanomas.
    Type: Grant
    Filed: June 25, 1987
    Date of Patent: March 14, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Walfred S. Saari
  • Patent number: 4739113
    Abstract: Novel chemical compounds are provided which selectively inhibit the metabolism of renal dipeptidase (E.C.3.4.13.11) and therefore are useful in combination with antibacterial products. These chemical compounds are (Z,Z)-.alpha.,.alpha.'-bis(2,2-disubstituted cyclopropanecarboxamido)-.alpha.,.alpha.'-alkadienedioic acids.
    Type: Grant
    Filed: May 30, 1986
    Date of Patent: April 19, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Anna Chen, Edward F. Rogers
  • Patent number: 4734497
    Abstract: A process is described for selectively obtaining 1-.beta.-methylcarbapenem intermediates. The desired chirality is obtained through the hydrogenation of certain bicyclic .beta.-lactam ring structures containing an exocyclic methylene double bond alpha to the .beta.-lactam ring, in the presence of a Group VIII metal hydrogenation catalyst. The hydrogenation results in a mixture of .alpha.- and .beta.-methyl epimers having a high .beta./.alpha.epimeric ratio. New 1-.beta.-methylcarbapenem intermediates made by the process are also described.
    Type: Grant
    Filed: September 5, 1986
    Date of Patent: March 29, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Lovji D. Cama, Susan M. Schmitt
  • Patent number: 4727062
    Abstract: Described are 3-halovinylglycines and their amino acid dipeptide and oligopeptide conjugates, a new class of efficient antibacterial agents, pharmaceutical compositions containing them as active ingredients, and methods of synthesis. The compounds are thought to interfere in bacterial cell wall synthesis.
    Type: Grant
    Filed: March 17, 1986
    Date of Patent: February 23, 1988
    Assignee: Merck & Co., Inc.
    Inventors: David Taub, Robert H. Abeles, Arthur A. Patchett
  • Patent number: 4715994
    Abstract: New 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids are described which display antibacterial activity and potentiate carbapenem antibiotics.
    Type: Grant
    Filed: November 5, 1986
    Date of Patent: December 29, 1987
    Assignee: Merck & Co., Inc.
    Inventors: William H. Parsons, William R. Schoen, Arthur A. Patchett, Masao Taniguchi
  • Patent number: 4695624
    Abstract: Covalently modified bacterial polysaccharides and proteins; covalent conjugates of such polysaccharides linked by a bigeneric spacer, which permits proof of covalency and facilitates purification of conjugated materials, with immunogenic bacterial membrane or other proteins, which conjugates are useful components of bacterial vaccines; and methods of preparing such polysaccharides, proteins and conjugates and of confirming the covalency of the linkage between polysaccharides and proteins.
    Type: Grant
    Filed: April 4, 1985
    Date of Patent: September 22, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Stephen Marburg, Richard L. Tolman, Peter J. Kniskern
  • Patent number: 4656036
    Abstract: The antibiotics Tejeramycin are active against gram negative and gram positive infections, especially against Pseudomonas aeruginosa. The antibiotics Tejeramycin are produced by the aerobic fermentation of Streptomyces griseus ATCC No. 39208 or 39209 in an assimilable aqueous nutrient medium.
    Type: Grant
    Filed: January 11, 1985
    Date of Patent: April 7, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth E. Wilson, Sheldon B. Zimmerman
  • Patent number: 4654359
    Abstract: Organic sulfoxides having a latent allyl group bound to the sulfur are enzyme inhibitors of the suicide or K.sub.cat type.
    Type: Grant
    Filed: August 29, 1985
    Date of Patent: March 31, 1987
    Assignee: Merck & Co., Inc.
    Inventor: Raymond A. Firestone
  • Patent number: 4653668
    Abstract: A container for storing and dispensing small objects, such as capsules or pills containing medicament, one at a time, consists of a receptacle containing, within itself, a delivery mechanism including a funnel-shaped exit port for capsules and a capsule or pill delivery tube at the end of said funnel-shaped exit designed to accommodate no more than one pill or capsule. This funnel divides the outer receptacle into an upper storage compartment and a lower delivery compartment. The receptacle also contains between the exit end of the receptacle and the delivery tube a resilient gate member positioned to prevent or allow escape of a capsule or pill from the delivery tube. The inner end of the receptacle is pressed into or twisted in the user's hand which moves the resiliently mounted gate members, thus opening the delivery tube and delivering a single small object to the user.
    Type: Grant
    Filed: June 27, 1985
    Date of Patent: March 31, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth J. Gibilisco, Stephen Degnen, Richard Borders
  • Patent number: 4639458
    Abstract: A direct compression tablet formulation containing a non-hydrated quinoline carboxylic acid type antibacterial agent.
    Type: Grant
    Filed: January 22, 1985
    Date of Patent: January 27, 1987
    Assignee: Merck & Co., Inc.
    Inventor: Ashok V. Katdare
  • Patent number: 4610820
    Abstract: In a process for the total synthesis of thienamycin from L-aspartic acid via intermediate III: ##STR1## R=H, blocking group or salt cation there is disclosed a process for preparing III via ##STR2## wherein R is a protecting group.
    Type: Grant
    Filed: October 11, 1985
    Date of Patent: September 9, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Ronald W. Ratcliffe, Thomas N. Salzmann
  • Patent number: 4609641
    Abstract: Peptides having the formula ##STR1## and their use as pharmaceuticals are disclosed.
    Type: Grant
    Filed: December 3, 1984
    Date of Patent: September 2, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Ben E. Evans, Kenneth E. Rittle
  • Patent number: 4595750
    Abstract: A process is described for selectively obtaining 1-.beta.-methylcarbapenem intermediates. The desired chirality is obtained through the hydrogenation of certain bicyclic .beta.-lactam ring structures containing an exocyclic methylene double bond alpha to the .beta.-lactam ring, in the presence of a Group VIII metal hydrogenation catalyst. The hydrogenation results in a mixture of .alpha.- and .beta.-methyl epimers having a high .beta./.alpha. epimeric ratio. New 1-.beta.-methylcarbapenem intermediates made by the process are also described.
    Type: Grant
    Filed: August 29, 1984
    Date of Patent: June 17, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Lovji D. Cama, Susan M. Schmitt
  • Patent number: 4594191
    Abstract: A non-fermentation process for preparing a benzodiazepinedione of the formula: ##STR1## and intermediates is disclosed.
    Type: Grant
    Filed: April 22, 1985
    Date of Patent: June 10, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger, Steven M. Pitzenberger
  • Patent number: 4587357
    Abstract: A process for direct preparation of enantiomers of a substituted fluorenyloxyacetic acid is disclosed. The acetic acid derivative is useful for treating brain edema.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: May 6, 1986
    Assignee: Merck & Co., Inc.
    Inventor: Apurba Bhattacharya
  • Patent number: 4582931
    Abstract: A process for the preparation of 2-Deutero-D-serine and its fluorination is disclosed.
    Type: Grant
    Filed: December 24, 1984
    Date of Patent: April 15, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. J. Grabowski, Paul J. Reider